W. R. Grace & — Merger or Acquisition (February 2021)
11 slides from W. R. Grace &'s merger presentation, Feb 26, 2021
Slide 1: Grace Expands Fast Growing Pharma Portfolio: Grace to Acquire Albemarle's Fine Chemistry Services Business
Grace Expands Fast Growing Pharma Portfolio Grace to Acquire Albemarle’s Fine Chemistry Services Business February 25, 2021
Slide 2: Statement Regarding Safe Harbor For Forward-Looking Statements
2021 W. R. Grace & Co. | 2 Statement Regarding Safe Harbor For Forward-Looking Statements This announcement contains forward-looking statements, that is, information related to future, not past, events. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “e
Slide 3: Transaction Overview
2021 W. R. Grace & Co. | 3 Attractive Valuation Financial Flexibility Strategically Compelling Timing / Closing Considerations ▪ $570 million purchase price, 9.5x full year run-rate 2021 EBITDA multiple ▪ Funded with $300 million in cash and $270 million in non-participating preferred equity ▪ Finan
Slide 4: Accelerates Strategy of Building Higher Growth Portfolio
2021 W. R. Grace & Co. | 4 Accelerates Strategy of Building Higher Growth Portfolio Accretive to revenue growth rate, EBITDA margin, and Adjusted EPS in 2021 at attractive valuation – Accretive revenue growth rate with EBITDA margins >35% – $570 million purchase price with ~$60 million full year run
Slide 5: Highly Complementary to Existing Pharma Portfolio
2021 W. R. Grace & Co. | 5 Highly Complementary to Existing Pharma Portfolio The Pharma business is the largest, fastest growing and most profitable business within Materials Technologies Leading supplier of silica materials and fine chemicals for global Pharmaceutical, Nutraceutical, and Agricultur
Slide 6: Strategically and Financially Compelling Acquisition
2021 W. R. Grace & Co. | 6 Strategically and Financially Compelling Acquisition 62%16% 22% Albemarle’s Fine Chemistry Services Business (“FCS”) develops and manufactures high-value regulatory starting materials (RSMs), intermediates, and active pharmaceutical ingredients (APIs) ▪ Key end-markets inc
Slide 7: Grace Offers A Compelling Investment Opportunity
2021 W. R. Grace & Co. | 7 Grace Offers A Compelling Investment Opportunity So Much More Than Refining Catalysts We are successfully building a higher growth portfolio ▪ SC and MT combined are 62% of our 2020 sales, 66% larger than RT ▪ RT's robust cash flow is a valuable asset that helps fund our g
Slide 8: Appendix
Appendix GRACE Talent | Technology | Trust
Slide 9: Appendix: Definitions and Reconciliations of Non-GAAP Measures
2021 W. R. Grace & Co. | 9 Appendix: Definitions and Reconciliations of Non-GAAP Measures Non-GAAP Financial Measures (A) In the above, Grace presents financial information in accordance with U.S. generally accepted accounting principles (U.S. GAAP), as well as the non-GAAP financial information des
Slide 10: Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued)
2021 W. R. Grace & Co. | 10 Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued) Non-GAAP Financial Measures In the 2020 first quarter, the definition of Adjusted EBIT was modified to adjust for the effects of interest and taxes on equity in earnings of unconsolidated affiliate
Slide 11: Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued)
2021 W. R. Grace & Co. | 11 Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued) Non-GAAP Financial Measures Grace is unable without unreasonable efforts to estimate the annual mark-to-market pension adjustment or future net income or diluted EPS. Without the availability of th